Zoetis

OverviewSuggest Edit

Zoetis is a producer of medicine and vaccinations for pets and livestock. The Company commercializes products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five major product categories: anti-infectives, vaccines, parasiticides, medicated feed additives, and other pharmaceuticals.

TypePublic
Founded1952
HQParsippany-Troy Hills, USMap
Websitezoetis.com
Employee Ratings3.5More
View Jobs (153)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)10,000(+9%)
Job Openings153
Revenue (FY, 2018)$5.8 B(+10%)
Share Price (Dec 2019)$124.3

Key People/Management at Zoetis

Juan Ramón Alaix

Juan Ramón Alaix

Chief Executive Officer
Heidi Chen

Heidi Chen

Executive Vice President and General Counsel
Glenn David

Glenn David

Executive Vice President and Chief Financial Officer
Andrew Fenton

Andrew Fenton

Executive Vice President and Chief Digital and Technology Officer
Catherine Knupp

Catherine Knupp

Executive Vice President and President, Research and Development
Roxanne Lagano

Roxanne Lagano

Executive Vice President, Chief Human Resources Officer and Communications
Show more

Zoetis Office Locations

Zoetis has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
10 Sylvan Way, Parsippany
Show all (1)

Zoetis Financials and Metrics

Zoetis Revenue

Zoetis's revenue was reported to be $5.83 b in FY, 2018
USD

Revenue (Q3, 2019)

1.6b

Gross profit (Q3, 2019)

1.1b

Gross profit margin (Q3, 2019), %

69.8%

Net income (Q3, 2019)

433.0m

Market capitalization (12-Dec-2019)

59.2b

Closing stock price (12-Dec-2019)

124.3

Cash (30-Sept-2019)

1.8b

EV

64.0b
Zoetis's current market capitalization is $59.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

4.6b4.8b4.8b4.9b5.3b5.8b

Revenue growth, %

5%0%3%9%

Cost of goods sold

1.7b1.7b1.7b1.8b1.9b

Gross profit

2.9b3.1b3.2b3.5b3.9b
Quarterly
USDQ4, 2013Q4, 2014Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

4.6b4.8b1.2b1.2b1.2b1.2b1.2b1.3b1.2b1.3b1.4b1.4b1.5b1.5b1.5b1.6b

Cost of goods sold

1.7b1.7b427.0m421.0m410.0m389.0m399.0m435.0m443.0m440.0m447.0m447.0m473.0m518.0m465.0m479.0m

Gross profit

2.9b3.1b748.0m793.0m831.0m773.0m809.0m912.0m788.0m829.0m919.0m968.0m1.0b937.0m1.1b1.1b

Gross profit Margin, %

63%64%64%65%67%67%67%68%64%65%67%68%68%64%70%70%
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.2b727.0m1.6b1.6b

Accounts Receivable

937.0m34.6m998.0m1.0b

Prepaid Expenses

201.0m228.0m271.0m

Inventories

1.5b1.5b1.4b1.4b
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q4, 2013Q1, 2014Q2, 2014Q3, 2014Q4, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

468.0m369.0m389.0m610.0m506.0m578.0m598.0m882.0m559.0m544.0m592.0m675.0m658.0m651.0m629.0m705.0m2.0b1.7b1.6b1.3b1.7b1.8b1.8b

Accounts Receivable

861.0m1.1b1.1b1.1b1.1b1.1b1.1b980.0m905.0m993.0m1.0b908.0m888.0m915.0m954.0m975.0m1.0b943.0m973.0m929.0m970.0m994.0m1.0b

Prepaid Expenses

188.0m227.0m228.0m219.0m205.0m207.0m204.0m205.0m213.0m235.0m264.0m236.0m257.0m235.0m265.0m353.0m357.0m229.0m288.0m315.0m255.0m306.0m322.0m

Inventories

1.1b1.3b1.3b1.3b1.3b1.3b1.4b1.3b1.3b1.4b1.4b1.5b1.5b1.6b1.5b1.5b1.5b1.4b1.4b1.4b1.4b1.4b1.4b
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

339.0m819.0m862.0m1.4b

Depreciation and Amortization

60.0m60.0m199.0m240.0m242.0m308.0m

Inventories

(262.0m)(101.0m)19.0m61.0m

Accounts Payable

17.0m(28.0m)(10.0m)37.0m
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q4, 2013Q1, 2014Q2, 2014Q3, 2014Q4, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

140.0m268.0m399.0m504.0m155.0m291.0m457.0m583.0m165.0m129.0m319.0m204.0m428.0m665.0m239.0m486.0m782.0m350.0m732.0m1.1b312.0m683.0m1.1b

Depreciation and Amortization

51.0m102.0m151.0m209.0m50.0m101.0m151.0m204.0m48.0m129.0m144.0m57.0m117.0m177.0m62.0m121.0m179.0m60.0m123.0m207.0m98.0m196.0m303.0m

Inventories

(104.0m)(16.0m)(134.0m)(142.0m)(3.0m)(87.0m)(133.0m)(52.0m)(46.0m)(35.0m)(33.0m)(23.0m)29.0m17.0m(50.0m)(103.0m)

Accounts Payable

(82.0m)(210.0m)(2.0m)30.0m(84.0m)(71.0m)(56.0m)(37.0m)(66.0m)(56.0m)(46.0m)(28.0m)(39.0m)(79.0m)(22.0m)(28.0m)
show all
USDY, 2019

EV/CFO

52.8 x

Financial Leverage

4.2 x
Show all financial metrics

Zoetis Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AbaxisMay 15, 2018$1.90 b

Zoetis Online and Social Media Presence

Zoetis's Trends

Embed Graph

Zoetis News and Updates

November 07, 2019

Zoetis shares jump 2.9% premarket after earnings top estimates

Zoetis Inc. shares rose 2.9% in premarket trade Wednesday, after the animal health company beat estimates for the third quarter. Parsippany, N.J.-based Zoetis said it had net income of $433 million. or 90 cents a share, n the quarter, up from $347 million, or 71 cents a share, in the year-earlier p…
October 06, 2019

Heroes to America's Animals: Meet the Winners of the 2019 American Humane Hero Veterinarian and Hero Veterinary Nurse Awards™, Presented by Zoetis

LOS ANGELES, Oct. 6, 2019 /PRNewswire/ -- Heroic canines were not the only honorees Saturday night at the ninth annual American Humane Hero Dog Awards®. America's first national humane organization also honored a couple of human beings – with the American Humane Hero Veterinarian and Hero...
October 03, 2019

Zoetis names Kristin Peck as CEO effective Jan 1, replacing Juan Ramon Alaix who is retiring

Zoetis Inc. said Thursday it has named Kristin Peck as chief executive effective Jan. 1, replacing Juan Ramon Alaix, who is retiring. Peck is currently executive vice president and group president responsible for U.S. operations, business development and strategy at the Parsippany, N.J.-based anima…
September 19, 2019

Factbox: Animal health sector aims to emulate Zoetis biotech leap

A commercial breakthrough in the field of complex therapeutic proteins for dogs by sector leader Zoetis has roused rivals to action in a hunt for biotechnology medicines to treat pets.
September 18, 2019

Dog Prescription Drugs Market Major Key Players Are Elanco Animal Health, Ceva Sante Animale, MSD Animal Health, Zoetis, Virbac, Dechra Vetoquinol, Animalcare Group

Latest Research: 2019 Global Dog Prescription Drugs Market Report Posted via Industry Today. Follow us on Twitter @IndustryToday
May 10, 2019

The Global Market for Pet Veterinary Drugs (2016-2025): Led by Zoetis, Bayer, Boehringer Ingelheim International, Merck Animal Health

DUBLIN, May 10, 2019 /PRNewswire/ -- The "Pet Veterinary Drugs Market" report has been added to ResearchAndMarkets.com's offering. The global Pet Veterinary Drugs Market reached USD 16,239.3 Million in 2018. Moreover, the market is expected to garner USD 21,205.2 Million by the end of...
Show more

 Zoetis Frequently Asked Questions

  • When was Zoetis founded?

    Zoetis was founded in 1952.

  • Who are Zoetis key executives?

    Zoetis's key executives are Juan Ramón Alaix, Heidi Chen and Glenn David.

  • How many employees does Zoetis have?

    Zoetis has 10,000 employees.

  • What is Zoetis revenue?

    Latest Zoetis annual revenue is $5.8 b.

  • What is Zoetis revenue per employee?

    Latest Zoetis revenue per employee is $582.5 k.

  • Who are Zoetis competitors?

    Competitors of Zoetis include Elanco, Dechra Pharmaceuticals and Aratana Therapeutics.

  • Where is Zoetis headquarters?

    Zoetis headquarters is located at 10 Sylvan Way, Parsippany, Parsippany-Troy Hills.

  • Where are Zoetis offices?

    Zoetis has an office in Parsippany-Troy Hills.

  • How many offices does Zoetis have?

    Zoetis has 1 office.